CAMBRIDGE, Mass. (AP) _ Bluebird Bio Inc. (BLUE) on Thursday reported a loss of $149 million in its fourth quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.72.
The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $2.83 per share.
The biotechnology company posted revenue of $19.2 million in the period, also topping Street forecasts. Nine analysts surveyed by Zacks expected $9.8 million.
For the year, the company reported that its loss widened to $555.6 million, or $10.68 per share. Revenue was reported as $54.6 million.
Bluebird shares have climbed 28 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $127.24, a decline of 39 percent in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLUE at https://www.zacks.com/ap/BLUE